drugset / Trial / NCT02476617

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

NCT02476617

Phase 3 Completed 25 enrolled AbbVie
NaSingle-groupOpen-labelTreatment

Summary

A study to evaluate immune restoration following removal of viral antigen in non-cirrhotic hepatitis C virus (HCV) genotype (GT) 1a treatment-naïve and pegylated-interferon (pegIFN)/ribavirin (RBV) treatment-experienced adults receiving treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir coadministered with ribavirin (RBV) for 12 weeks.

Timeline

Start
2015-06
Primary completion
2016-08
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule 1000 mg
Subject Ribavirin Small molecule 1200 mg
Subject Ritonavir Other / unclassified 100 mg
Subject dasabuvir Small molecule 250 mg
Subject ombitasvir Small molecule 25 mg
Subject paritaprevir Small molecule 150 mg